[1]
Sleire, L.; Førde, H.E.; Netland, I.A.; Leiss, L.; Skeie, B.S.; Enger, P.∅. Drug repurposing in cancer; Pharma. Res, 2017, pp. 74-91.
[http://dx.doi.org/10.1016/j.phrs.2017.07.013] [PMID: 28712971]
[http://dx.doi.org/10.1016/j.phrs.2017.07.013] [PMID: 28712971]
[2]
Khachigian, L.M. Repurposing drugs for skin cancer. Curr. Med. Chem., 2020, 27(42), 7214-7221.
[http://dx.doi.org/10.2174/0929867327666191220103901] [PMID: 31858902]
[http://dx.doi.org/10.2174/0929867327666191220103901] [PMID: 31858902]
[3]
Torralba, M.; Farra, R.; Maddaloni, M.; Grassi, M.; Dapas, B.; Grassi, G. Drugs repurposing in high-grade serous ovarian cancer. Curr. Med. Chem., 2020, 27(42), 7222-7233.
[http://dx.doi.org/10.2174/0929867327666200713190520] [PMID: 32660396]
[http://dx.doi.org/10.2174/0929867327666200713190520] [PMID: 32660396]
[4]
Fernandes, S.; Cassani, M.; Pagliari, S.; Filipensky, P.; Cavalieri, F.; Forte, G. Tumor in 3D: in vitro complex cellular models to improve nanodrugs cancer therapy. Curr. Med. Chem., 2020, 27(42), 7234-7255.
[http://dx.doi.org/10.2174/0929867327666200625151134] [PMID: 32586245]
[http://dx.doi.org/10.2174/0929867327666200625151134] [PMID: 32586245]